Vijaya Diagnostic Centre Ltd

- There is no mention of any current or planned fundraising through debt or equity in the transcript. - The company reported having a surplus cash balance of around Rs. 235 crores as of September 30, 2025, indicating a strong liquidity position. - Discussions around capital expenditure indicate internal funding plans (Rs.160 crores CAPEX for FY26 and Rs.100-120 crores for FY27), without reference to external fundraising. - No questions or management comments suggest any intention to raise funds via equity or debt in the near future. - Overall, Vijaya Diagnostic Centre Limited appears to be financially self-sufficient with no immediate plans for fundraising.

- FY26 CAPEX for new centres is about Rs.160 crores, majority incurred by H1FY26. - FY27 CAPEX expected between Rs.100 to Rs.120 crores, lower than FY26. - CAPEX focused on opening new hubs and spokes in various geographies including Bangalore, Kolkata, Pune, and core markets. - Two hubs opened recently in Nandyal and Khammam; two more hubs planned in Q3 FY26. - Plans to increase hubs from current two to five by end of FY27. - Long-term expansion plan includes lease properties for new hubs/spokes. - Break-even for new centres generally expected within one year. - Strategic investment in technology planned with the recruitment of a new CTO to enhance IT and operational capabilities.

- Vijaya Diagnostic Centre targets around 15% overall year-level growth. - Radiology volume growth guidance is around 13%, with realization growth of 1.5-2%. - Growth is volume-driven across new geographies (Bangalore, Kolkata, Pune), especially in initial 1-1.5 years, with limited price hikes expected near-term. - Multiple new hubs and spokes expected to be operational, increasing volume and contribution from advanced radiology. - Bangalore hubs expected to grow by volume for 1-1.5 years; some hubs have broken even earlier. - Pune hubs expected to break even within about a year; some cleanup activities delayed ramp-up. - Despite seasonality and weather factors impacting pathology volumes temporarily, the company is optimistic on steady normalized growth. - Strategic location choice and differentiation expected to bolster growth against competition. - The company is confident of surpassing prior guidance on revenue and EBITDA margin in coming periods.

- Vijaya Diagnostic Centre projects around 15% CAGR revenue growth over the next three years, with efforts ongoing to potentially exceed this. - EBITDA margins are expected to be around 40% for FY27, slightly improving as new centers break even. - CAPEX for FY27 is anticipated between Rs.100 to Rs.120 crores, lower than FY26’s Rs.160 crores, supporting margin expansion. - Break-even for new hubs is targeted within one year, with some new centers achieving earlier break-even. - Growth is expected to be volume-driven across new geographies (Bangalore, Kolkata, Pune) for the next 1–1.5 years, with limited price hikes unless input costs necessitate. - The company remains confident about surpassing current EBITDA margin guidance, having delivered ~39.2% in recent quarters vs. guided 38%-39%. - Early signs indicate strong radiology growth (~16%) and improved operations post-expansion support promising operating earnings growth.

The transcript from Vijaya Diagnostic Centre Limited's earnings call on November 4, 2025, does not explicitly mention a current or expected order book or pending orders. However, relevant insights include: - The company is actively expanding through opening new hubs and spokes across various cities like Bangalore, Pune, Kolkata, and Hyderabad. - They plan to add 4-5 hubs and 10-12 spokes by the end of FY26. - CAPEX for H2FY26 stands at Rs.160 crores (mostly incurred in H1), with an expected Rs.100-120 crores CAPEX planned for FY27. - Focus is on stabilizing new centers before further expansion, especially in Pune. - Growth is driven by volume increase rather than pricing hikes. - No direct figures or guidance on order book or pending orders were disclosed in the call.